Clinical Guidelines

Enhancing Immune Thrombocytopenia Education and Support: Insights From a Learning Exchange Program

Share

Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by the destruction of megakaryocytes or antibodies mediating platelet loss, resulting in low platelet counts and potential severe bleeding complications. The disorder manifests with various bleeding symptoms and has a distinct incidence in children and adults. Treatment strategies depend on individual factors, including disease duration and severity, and may involve corticosteroids, immunoglobulins, or thrombopoietin receptor agonists. Emerging therapeutics and patient advocacy play a vital role in addressing unmet needs and enhancing quality of life for affected individuals.

Original Source(s)

Enhancing Immune Thrombocytopenia Education and Support: Insights From a Learning Exchange Program

  • by Michael Tarantino, MD, David Dubinski, MBA, Corey Falcon, MD, Leslie Ferber, MPH, Patrick Foy, MD, Stephanie Johnston, MSN, APRN, FNP-C, AOCNP, Susan Kirk, PA-C, Michele P. Lambert, MD, MSTR, Farishta Manzoor, PharmD, Vlad Radulescu, MD, Iberia Romina Sosa, MD, PhD, Porcher Scott

  • March 9, 2026

  • 17 min

Related Content

Optimizing the Care of Patients With Higher-Risk Myelofibrosis

Navigating Complex Cases With Empathetic Communication

Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Monocytosis

The second case in our series on myeloid neoplasms